Serum Meteorin‐like is associated with weight loss in the elderly patients with chronic heart failure

Cai, Juan; Wang, Qiming; Li, Jiawen; Xu, Fan; Bu, Yun-Ling; Wang, Man; Lü, Xiang; Gao, Wei

doi:10.1002/jcsm.12865

Cited by 13 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies showed that serum IL‐41 levels were reduced in many diseases, especially in patients with inflammation‐related diseases. Cai et al 20 found that serum IL‐41 levels were lower in chronic heart failure patients when compared to control subjects. Several studies demonstrated that serum IL‐41 levels were decreased in T2D patients compared with the healthy controls 21–23 .…”

Section: Discussionmentioning

confidence: 99%

Decreased serum interleukin‐41/Metrnl levels in patients with Graves' disease

Gong

Huang

Weng

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background: Interleukin (IL)-41, also known as Metrnl, is a novel immunomodulatory cytokine, which is involved in the pathogenesis of many inflammatory and metabolic diseases, but its role in thyroid autoimmune diseases is not clear. The aim of this study was to evaluate the serum IL-41 levels in patients with Graves' disease (GD) and its relationship with GD.Methods: This study included a total of 49 GD patients and 47 age-and sex-matched healthy individuals. All baseline data were obtained by physical examination. Free triiodothyronine 3 (FT3), free triiodothyronine 4 (FT4), thyroid-stimulating hormone (TSH), anti-thyroglobulin antibodies (TgAb), thyroid peroxidase antibody (TPOAb), and thyrotropin receptor antibody (TRAb) levels in plasma of GD patients were measured by chemiluminescence. The high-sensitivity C-reactive protein (CRP) and white blood cell count (WBC) were detected using automated biochemical analyzer. Serum IL-41 levels were measured by enzyme-linked immunosorbent assay.Results: Serum IL-41 levels in patients with GD were significantly lower than those in healthy controls (201.0 vs. 260.8 pg/mL, p < 0.05). There was a significant positive correlation between IL-41 level and CRP (r = 0.2947, p = 0.0385) and WBC (r = 0.4104, p = 0.0034) in GD patients. CRP was positively correlated with TRAb (r = 0.2874, p = 0.0452) and TSH (r = 0.3651, p = 0.0099) levels in GD patients. Conclusions:This study demonstrates that GD patients have decreased serum IL-41 levels, and IL-41 plays a potential role in abnormal immune response of GD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Decreased serum interleukin‐41/Metrnl levels in patients with Graves' disease

Gong

Huang

Weng

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Additionally, logistic regression analysis revealed that reduced circulating Metrnl levels were independently associated with increased risk of hyper-TG, hyper-TC, and hyper-LDL in the current study. Sparklingly, results from clinical studies have revealed that decreased systemic Metrnl levels are related to coronary artery disease and chronic heart failure ( 33 , 34 ). Besides, very recently, it has been indicated that the lack of Metrnl is prone to promote cardiac hypertrophy, and the overexpression or treatment of Metrnl can activate the PPARγ coactivator-1α (PGC1-α) and fatty acid oxidation (FAO) pathways of cardiomyocytes to protect heart against cardiac dysfunction in mice ( 35 ).…”

Section: Discussionmentioning

confidence: 99%

Serum Metrnl levels are decreased in subjects with overweight or obesity and are independently associated with adverse lipid profile

et al. 2022

View full text Add to dashboard Cite

BackgroundMeteorin-like (Metrnl), a novel adipokine, is highly expressed in adipose tissue and has a beneficial effect on energy metabolism. However, data on circulating Metrnl levels in obesity are scarce and inconsistent. This study aimed to evaluate the serum levels of Metrnl in adults with obesity and its association with glucose and lipid metabolism.Methods182 subjects were included in the cross-sectional study. The participants were divided into three groups according to BMI: normal (n = 95), overweight (n = 46), and obesity (n = 41). Serum Metrnl concentrations were measured by enzyme-linked immunosorbent assay.ResultsSerum Metrnl levels in overweight or obese subjects were significantly lower than in the normal group. Circulating Metrnl levels were negatively correlated with TG, TC, LDL-C, and sdLDL and positively correlated with HDL-C before and after adjusting for age, sex, BMI, diabetes, HOMA-IR, and eGFR (all P < 0.05). Furthermore, logistic regression analysis indicated that compared with the highest tertile, the lowest tertile of Metrnl levels were significantly associated with the presence of hyper-TG, hyper-TC, and Hyper-LDL after full adjustment (all P for trend < 0.05).ConclusionsSerum Metrnl levels were reduced in individuals with overweight or obesity and were independently associated with adverse lipid profile, suggesting that modifying circulating Metrnl levels may serve as a potential therapeutic target for atherogenic dyslipidemia.

show abstract

“…Results from experimental studies have shown that subfatin can reduce doxorubicin-induced cardiotoxicity by activating the cyclic AMP/protein kinase A/Sirtuin1 pathway, and reduce cardiomyocyte apoptosis caused by ischaemia/reperfusion injury through activation of AMP-activated protein kinase/p21-activated kinase 2 signalling ( 14 , 15 ). Cai et al showed that low serum Metrnl concentrations in elderly patients with congestive heart failure were associated with weight loss and the severity of cardiac dysfunction ( 16 ). Our results demonstrated that the sensitivity and specificity was 64% and 69%, respectively, when differentiating patients with AMI (STEMI and NSTEMI) from those without AMI, whereas the sensitivity was 94% and specificity was 41% when in differentiating STEMI from NSTEMI patients.…”

Section: Discussionmentioning

confidence: 99%

Subfatin concentration decreases in acute coronary syndrome

Yılmaz

Göktekin

İlhan

2022

Biochem. med. (Online)

View full text Add to dashboard Cite

Introduction We investigated the association of serum subfatin concentration and acute myocardial infarction (AMI) in patients with ST-elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI). Materials and methods In this study, patients who presented with chest pain (STEMI, NSTEMI, or non-cardiac chest pain) were included, i.e. 49 patients with non-cardiac chest pain (control) and 66 patients hospitalised with AMI. In the AMI group, 35 patients had NSTEMI and 31 had STEMI. Serum subfatin concentrations were determined via enzyme-linked immunosorbent assay (ELISA). Descriptive data on the patients and their comorbidities were recorded, and subfatin concentrations were analysed. Results Subfatin concentrations were significantly different in the control, STEMI and NSTEMI groups (P = 0.002). In addition, subfatin concentrations were significantly lower in patients in the NSTEMI group than those in the control group (P < 0.001), but there was no significant difference between STEMI and the control group (P = 0.143). The receiver operating characteristic (ROC) analysis performed for differentiating the AMI and control groups found that subfatin had 64% sensitivity and 69% specificity, whereas troponin had 59% sensitivity and 95% specificity. In patients with AMI, the ROC analysis for differentiating NSTEMI from STEMI found that subfatin had 94% sensitivity and 41% specificity, while troponin had 65% sensitivity and 88% specificity. Conclusions Subfatin concentrations were lower in patients without STEMI than in patients with STEMI. Subfatin concentration is associated with NSTEMI.

show abstract

Serum Meteorin‐like is associated with weight loss in the elderly patients with chronic heart failure

Cited by 13 publications

References 33 publications

Decreased serum interleukin‐41/Metrnl levels in patients with Graves' disease

Decreased serum interleukin‐41/Metrnl levels in patients with Graves' disease

Serum Metrnl levels are decreased in subjects with overweight or obesity and are independently associated with adverse lipid profile

Subfatin concentration decreases in acute coronary syndrome

Contact Info

Product

Resources

About